InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (12 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
12
T+90 hit rate
40%
T+90 mean return
-13.1%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Harris Erik, Vice-Président Exécutif et Directeur Commercial. Insider active across 2 companies, notably Ultragenyx Pharmaceutical Inc.. In total, 19 filings have been recorded. Breakdown: 0 buy · 12 sells. Total volume traded: €630k. Activity tracked since 6 May 2021. The latest transaction was disclosed on 1 March 2025 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations19 total
16,813 shares0Common StockSEC:0000950170-25-032773:0
5,967 shares0Common StockSEC:0001714899-24-000134:0
19,400 shares0Common StockSEC:0000950170-24-026629:0
6,000 shares@ US$37.9633.7% of flowCommon StockSEC:0001209191-23-048491:0
305 shares@ US$48.202.1% of flowCommon StockSEC:0001209191-23-038885:0
4,216 shares0Common StockSEC:0001714899-23-000094:0
2,663 shares0Common StockSEC:0001209191-23-016039:0
295 shares@ US$54.780.0006% mcap3.8% of flowCommon StockSEC:0001209191-22-038774:0
2,713 shares@ US$66.620.0065% mcap39.9% of flowCommon StockSEC:0001209191-22-015830:0
6,869 shares0Common StockSEC:0001714899-22-000024
6,869 shares0Common StockSEC:0001714899-22-000024:0
303 shares@ US$81.140.0009% mcap5.2% of flowCommon StockSEC:0001209191-21-060760:0
303 shares@ US$81.143.4% of flowCommon StockSEC:0001209191-21-060760
375 shares@ US$91.534.6% of flowCommon StockSEC:0001209191-21-045972
375 shares@ US$91.530.0012% mcap7.2% of flowCommon StockSEC:0001209191-21-045972:0
437 shares@ US$94.630.0014% mcap8.6% of flowCommon StockSEC:0001209191-21-042812:0
437 shares@ US$94.635.5% of flowCommon StockSEC:0001209191-21-042812
307 shares@ US$113.680.0012% mcap7.2% of flowCommon StockSEC:0001209191-21-031378:0
307 shares@ US$113.687.2% of flowCommon StockSEC:0001209191-21-031378
19 of 19 declarations
About Harris Erik
Harris Erik is the Executive Vice President and Chief Commercial Officer of Ultragenyx Pharmaceutical Inc. and Denali Therapeutics Inc. In these roles, he is responsible for commercial strategy and business development, contributing to the growth of both companies in the biopharmaceutical sector.
